T-cell therapy involves the programming or activation of specialized cells (T-cells) in the immune system that are capable of killing cancer cells. Depending on the type of T-cell therapy, the cells can be acquired from the patient or a donor. When acquired from donors, it is called adoptive immunotherapy.
T-cell therapy has been described as a "living drug" - combining the specificity of antibodies (targeting a molecule on the tumor such as cd10) with the killing power of t-cells.
Efficacy of this approach is dependent on the ability of the enhanced cells to expand and persist in the body after being given to the patient by vein. The safety of this treatment can be a concern as this approach can lead to serious inflammatory reactions.
.gif){kind=small}
